Figure 2.
Disease-free survival (DFS) and overall survival (OS) curves stratified by intratumoural hENT1 expression. AGC (+) indicates subgroups of patients who received adjuvant gemcitabine-based chemotherapy; AGC (−) indicates subgroups of patients who did not receive adjuvant gemcitabine-based chemotherapy. (A) DFS curves in AGC (+) patients (P=0.005). (B) DFS curves in AGC (−) patients (P=0.796). (C) OS curves in AGC (+) patients (P=0.036). (D) OS curves in AGC (−) patients (P=0.913).